An observational study in Non-small Cell Lung Cancer, sponsored by Shanghai Pulmonary Hospital, Shanghai, China. Status unknown at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2020-03-24.
Sponsored by Shanghai Pulmonary Hospital, Shanghai, China · Observational
Study on the tumor immune escape in advanced non-small cell lung cancer patients with EGFR and ALK mutant negative by NGS combined with RNAseq
Study on the tumor immune escape in advanced non-small cell lung cancer patients with EGFR and ALK mutant negative by NGS combined with RNAseq. Detecting non-small cell lung cancer patient NGS and RNAseq data before first-line chemotherapy, after two cycles chemotherapy and after disease progression.
7,243 studies on the registry are indexed under Lung Neoplasms; 1,557 are open to participants now.
This study's planned enrollment of 100 is below the median of 189 across 1,514 observational studies indexed under Lung Neoplasms.
Browse Lung Neoplasms studies →Shanghai Pulmonary Hospital, Shanghai, China is the lead sponsor of 149 studies on the registry; 91 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Non-small cell lung cancer patient First-line chemotherapy with platinum-based chemotherapy Without EGFR and Alk mutation
Non-small cell lung cancer patient First-line chemotherapy with platinum-based chemotherapy
Exclusion Criteria:
EGFR mutant positive Alk mutant positive
Different detecting time
numbers of immune cells
detecting numbers of immune cells before first-line chemotherapy, after two cycles chemotherapy and after disease progression
Time frame: 24 months
numbers of tumor mutations
detecting numbers of tumor mutations before first-line chemotherapy, after two cycles chemotherapy and after disease progression
Time frame: 24 months
Plan to share: Undecided
This study is status unknown, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Shanghai Pulmonary Hospital, Shanghai, China